TABLE 3.
Antibacterial activity of WLBU2 is not strain specifica
| P. aeruginosa strain | MBC (μM)
|
|
|---|---|---|
| WLBU2 | LL37 | |
| PA1244 | 0.3 | 2 |
| PACO1* | 0.5 | 2 |
| PACO3* | 0.3 | 1 |
| PACO4 | 0.5 | 2 |
| PACO6 | 0.5 | 2 |
| PACO7* | 0.5 | 2 |
| PACO8 | 0.3 | 1 |
| PACO9 | 0.3 | 1 |
| PACO10 | 0.3 | 2 |
| PACO11 | 0.5 | 2 |
| PACO12 | 0.5 | 2 |
| PACO13* | 0.5 | 2 |
| PACO14 | 0.3 | 2 |
| ATCC 19142* | 0.3 | 5 |
| ATCC 33468* | 0.3 | 2 |
| PAO1 | 0.5 | 1 |
a
To investigate whether the potent activity displayed by WLBU2 was dependent on the specificity of the clinical strains, we performed standard bacterial killing assays (in PBS) with a panel of 16 strains of P. aeruginosa, 6 of which were of mucoid phenotype. The peptide not only maintained its potent effects against all of these strains but also demonstrated a 4- to 13-fold-higher bactericidal activity than that of LL37. The data tabulated are representative of two experimental trials. *, Mucoid type.